Phase 2 Trial Update of Ponatinib for Chronic Myeloid Leukemia and Philadelphia-positive Acute Lymphoblastic Leukemia

Share this content:

Ariad Pharmaceuticals announced updated clinical data from the pivotal PACE trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to Sprycel (dasatinib; Bristol-Myers Squibb) or Tasigna (nilotinib; Novartis) or who have the T315I mutation. These data show that 54% of chronic-phase CML patients in the trial, including 70% of patients who have a T315I mutation, achieved a major cytogenetic response.

Efficacy data were reported on 444 treated patients in six pre-specified cohorts receiving 45mg of ponatinib administered orally once daily. Patients were assigned to a cohort based on their phase of disease (chronic-phase, accelerated-phase or blast-phase CML/Ph+ALL) and T315I mutation status (with or without the mutation). Based on assessment of all evaluable chronic-phase patients in the trial, 54% achieved a major cytogenetic response (MCyR), with 44% achieving a complete cytogenetic response (CCyR). The median follow up of the chronic-phase CML patients was 10.1 months. MCyR was the primary end-point for chronic-phase CML patients. Of the 64 evaluable chronic-phase CML patients with the T315I mutation, 70% of these patients achieved a MCyR, with 66% achieving a CCyR. The MCyR rate in evaluable chronic-phase patients without the T315I mutation was 49%.

There were a total of 19 chronic-phase patients treated with ponatinib in the PACE trial who had previously received only one tyrosine kinase inhibitor (TKI). Thirteen of these patients had previously been treated with Gleevec (imatinib; Novartis) only and six had previously received either dasatinib or nilotinib. Of the 19 patients who received ponatinib following treatment with only one prior TKI, 84% achieved a MCyR.

Major hematologic response (MaHR) was the primary end-point in accelerated and blast-phase CML or Ph+ALL patients in the trial. Sixty percent of accelerated-phase patients in the resistant or intolerant cohort achieved a MaHR. Fifty percent of accelerated-phase patients with the T315I mutation achieved a MaHR. Thirty five percent of blast-phase CML or Ph+ALL patients in the resistant or intolerant group achieved a MaHR. Similarly, 33% of blast-phase CML or Ph+ALL patients with the T315I mutation also had a MaHR.

Thirty four percent of accelerated phase patients and 27% of blast phase or Ph+ALL patients in the resistant or intolerant cohorts achieved a MCyR. Twenty percent of patients in accelerated phase and 23% of patients in blast phase or Ph+ALL in this same group achieved a CCyR.

Ponatinib is an oral multi-targeted kinase inhibitor being developed for the treatment of hematological cancers. 

For more information call (877) 621-2302 or visit

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs